HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Purported ‘Cancer Cure’ Linked To Heart Toxicity Is US FDA’s Latest Warning Target In Supplements

Executive Summary

The ingredient, cesium chloride, also was the subject of a citizen petition by consumer advocacy group Public Citizen asking the FDA to prohibit its use in supplements. The FDA has warned five firms marketing products labeled as supplements and containing cesium chloride.

You may also be interested in...



FDA Strengthens Compounding Safety with Cesium Ban And Research Collaboration

FDA has taken additional steps to make drug compounding safer for patients, including a ban on cesium chloride because of “significant safety risks” it poses and a pair of university research collaborations to help further develop a list of bulk drug ingredients that can be safely compounded.

SARMs Spells Latest 'Synthetic Steroids' FDA Finds In Supplements

FDA warns three US firms marketing products labeled as dietary supplements but containing selective androgen receptor modulators, SARMs, anabolic steroid-like ingredients that have the potential to increase the risk of heart attack and stroke and for which long-term effects are unknown.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150569

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel